Summary of Study ST002383
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001533. The data can be accessed directly via it's Project DOI: 10.21228/M8J99C This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST002383 |
Study Title | Metabolomics of B-cell Acute Lymphoblastic Leukemia in Response to Adipocyte Conditioned Media |
Study Type | Untargeted MS |
Study Summary | Adipocyte conditioned media (ACM), stromal cell conditioned media (SCM) and unconditioned media (UCM) were added to B-cell Acute Lymphoblastic Leukemia cells (REH and RCH-AcV) either with or without methotrexate (MTX). The metabolomic profiles of the cells was determined by mass spectrometry. |
Institute | Emory University |
Department | Pediatrics |
Laboratory | Joshua Chandler, PhD |
Last Name | Chandler |
First Name | Joshua |
Address | 2015 Uppergate Drive NE, Atlanta, GA 30322 |
joshua.chandler@emory.edu | |
Phone | 404-727-3536 |
Submit Date | 2022-10-07 |
Num Groups | Two sets of two sets of three groups (MTX and no-MTX, REH and RCH-AcV, ACM vs SCM vs UCM) |
Total Subjects | 3 replicates of each group (36 total) |
Publications | submitted to JNCI |
Raw Data Available | Yes |
Raw Data File Type(s) | mzML |
Analysis Type Detail | LC-MS |
Release Date | 2023-06-07 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR002484 |
Treatment Summary: | REH and RCH-AcV were maintained in RPMI1640 (cat#10-041-CV, Corning, Glendale, AZ), supplemented with 20% FBS (cat#S11550, BioTechne, Minneapolis, MN). OP-9 bone marrow stromal cells were maintained in α-MEM (cat#15-012-CV, Corning, Glendale, AZ) supplemented with 20% FBS. For adipocyte differentiation, 105 OP-9 cells were plated in 6-well plates in DMEM (cat#10-017-CV, Corning, Glendale, AZ) supplemented with 10% FBS as previously described [18, 26]. After 24 hours of culture, the media was removed and switched to differentiation media which is composed of α-MEM supplemented with 1.8mM oleate (cat#O7501, Sigma, St. Louis, MO) bound to BSA (cat#A6003, Sigma, St. Louis, MO) with molar ratio 5.5:1 along with 175nM insulin (cat#I6634, Sigma, St. Louis, MO) and 0.2% FBS. ACM was collected after 3 days of differentiation and used in the experiments describe in this study. For SCM, OP-9 cells were plated in DMEM supplemented with 10% FBS and conditioned media were collected on day 3 of culture. Human B-ALL cell lines (REH and RCH-AcV) were cultured for 24 hours in UCM, SCM, or ACM. Additionally, methotrexate (MTX)-treated human B-ALL cells were cultured for an additional 12 hours of treatment with MTX (50nM for REH and 70 nM for RCH-AcV). This timepoint was chosen due to our prior work in this system to avoid submitting mostly apoptotic cells for analysis. |
Treatment Compound: | adipocyte- , stromal cell-, and un- conditioned media; methotrexate or not |
Treatment Dosevolume: | methotrexate: 50-70 nM |
Treatment Doseduration: | conditioned medias: 24 hr; methotrexate: additional 12 hr |
Treatment Vehicle: | methotrexate: DMSO |